NDAORALSUSPENSIONPriority Review
Approved
Apr 2025
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
ELIQUIS (apixaban) by Bristol Myers Squibb is fxa. First approved in 2025.
Drug data last refreshed 4h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ELIQUIS (apixaban) is an oral anticoagulant that selectively inhibits Factor Xa, preventing thrombin generation and thrombus development without requiring antithrombin III. It is used to reduce the risk of stroke and systemic embolism in patients with atrial fibrillation and for treatment and prevention of deep vein thrombosis and pulmonary embolism. The drug indirectly inhibits platelet aggregation while having no direct effect on platelet function.
$18.3BPart D
GrowthGrowing
14.7 years to LOEStrong commercial trajectory with $18.3B in Part D spending and 21M+ claims reflects a mature, high-volume franchise supporting large regional and field-based teams.
Mechanism of Action
FXa. It does not require antithrombin III for antithrombotic activity. Apixaban inhibits free and clot-bound FXa, and prothrombinase activity. Apixaban has no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting FXa, apixaban…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban
Started Nov 2025
96 enrolled
Drug Drug Interaction (DDI)
REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults
Started Jun 2025
2,000 enrolled
Venous Thromboembolism (VTE)
Treatment With Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus After Acute Myocardial Infarction
Started Apr 2025
212 enrolled
Left Ventricular ThrombusAcute Myocardial Infarction
Bioequivalence Study of Apixaban 5 mg Film-coated Tablets in Healthy Thai Volunteers
Started Aug 2024
28 enrolled
Healthy Volunteer
Treatment of Post-Punch Biopsy Bleeding in Apixaban-Treated Patients Using Self-Administered BXP154B
Started Jan 2024
24 enrolled
Wound Bleeding
Worked on ELIQUIS at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.